Key result
Ischaemic stroke patients exhibited lower increments in CD62P surface expression and higher increments in CD40L expression and monocyte-platelet aggregates (all p<0.01) compared with controls.
Why the study?
Does platelet reactivity differ in patients after ischaemic stroke compared to controls over a 90-day period?
Population
186 subjects total: 86 patients after an ischaemic stroke, 62 disease controls, and 38 healthy volunteers.
Design
Cohort
Follow-up
90 days
Authors
Loading...
Altered platelet reactivity persists 90 days post-stroke; hypothesis-generating for secondary prevention strategies but should not yet change practice.
Observational (n=186)
Does platelet reactivity differ in patients after ischaemic stroke compared to controls over a 90-day period?
p-value: p=<0.01
Platelet reactivity remains chronically altered in patients up to 3 months after an ischaemic stroke despite secondary prevention.
Łukasik et al. (2011) conducted an observational in Ischaemic stroke (n=186). Ischaemic stroke vs. Disease controls and healthy volunteers was evaluated on Platelet reactivity in response to TRAP stimulation (increment in surface expression of CD62P, CD40L and monocyte-platelet aggregate formation) (p=<0.01). Ischaemic stroke patients exhibited lower increments in CD62P surface expression and higher increments in CD40L expression and monocyte-platelet aggregates (all p<0.01) compared with controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: